filename,file_path,size_mb,file_type,num_pages,release_date
Supplemental-Index-12-22-21.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_22122021/Supplemental-Index-12-22-21.pdf,1.94,pdf,17.0,22122021
125742_S2_M5_54_ezeanolue-e-2019.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01082022/125742_S2_M5_54_ezeanolue-e-2019.pdf,39.71,pdf,195.0,01082022
FDA-CBER-2021-5683-0396196_125742_S1_M5_bnt162-01-S-D-supppe.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01082022/FDA-CBER-2021-5683-0396196_125742_S1_M5_bnt162-01-S-D-supppe.xpt,0.01,xpt,,01082022
FDA-CBER-2021-5683-0396193 to -0396194_125742_S1_M5_c4591001-S-D-supppe.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01082022/FDA-CBER-2021-5683-0396193 to -0396194_125742_S1_M5_c4591001-S-D-supppe.xpt,0.01,xpt,,01082022
FDA-CBER-2021-5683-0396187_125742_S1_M5_c4591001-S-D-pr.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01082022/FDA-CBER-2021-5683-0396187_125742_S1_M5_c4591001-S-D-pr.xpt,0.02,xpt,,01082022
FDA-CBER-2021-5683-0396188 to -0396192_125742_S1_M5_c4591001-S-D-suppmo.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01082022/FDA-CBER-2021-5683-0396188 to -0396192_125742_S1_M5_c4591001-S-D-suppmo.xpt,0.06,xpt,,01082022
FDA-CBER-2021-5683-0308157 to -0396186_125742_S1_M5_c4591001-S-D-suppface.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01082022/FDA-CBER-2021-5683-0308157 to -0396186_125742_S1_M5_c4591001-S-D-suppface.xpt,466.78,xpt,,01082022
FDA-CBER-2021-5683-0396197_125742_S1_M5_bnt162-01-S-D-supprp.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01082022/FDA-CBER-2021-5683-0396197_125742_S1_M5_bnt162-01-S-D-supprp.xpt,0.0,xpt,,01082022
FDA-CBER-2021-5683-0396198_125742_S1_M5_bnt162-01-S-D-te.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01082022/FDA-CBER-2021-5683-0396198_125742_S1_M5_bnt162-01-S-D-te.xpt,0.01,xpt,,01082022
FDA-CBER-2021-5683-0396195_125742_S1_M5_bnt162-01-S-D-relrec.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01082022/FDA-CBER-2021-5683-0396195_125742_S1_M5_bnt162-01-S-D-relrec.xpt,0.0,xpt,,01082022
FDA-CBER-2021-5683-0396199_125742_S1_M5_bnt162-01-S-D-tv.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01082022/FDA-CBER-2021-5683-0396199_125742_S1_M5_bnt162-01-S-D-tv.xpt,0.0,xpt,,01082022
FDA-CBER-2021-5683-0396228-0396233_125742_S1_M5_bnt162-01-S-D-rp.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01092022/FDA-CBER-2021-5683-0396228-0396233_125742_S1_M5_bnt162-01-S-D-rp.xpt,0.06,xpt,,01092022
FDA-CBER-2021-5683-0396239-0396241_125742_S1_M5_bnt162-01-S-D-suppeg.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01092022/FDA-CBER-2021-5683-0396239-0396241_125742_S1_M5_bnt162-01-S-D-suppeg.xpt,0.01,xpt,,01092022
FDA-CBER-2021-5683-0396249-0396254_125742_S1_M5_bnt162-01-S-D-xb.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01092022/FDA-CBER-2021-5683-0396249-0396254_125742_S1_M5_bnt162-01-S-D-xb.xpt,0.04,xpt,,01092022
FDA-CBER-2021-5683-0396242-0396246_125742_S1_M5_bnt162-01-S-D-suppxa.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01092022/FDA-CBER-2021-5683-0396242-0396246_125742_S1_M5_bnt162-01-S-D-suppxa.xpt,0.02,xpt,,01092022
FDA-CBER-2021-5683-0396255-0484341_125742_S1_M5_c4591001-S-Supp-D-suppface.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01092022/FDA-CBER-2021-5683-0396255-0484341_125742_S1_M5_c4591001-S-Supp-D-suppface.xpt,467.08,xpt,,01092022
FDA-CBER-2021-5683-0396247-0396248_125742_S1_M5_bnt162-01-S-D-ta.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01092022/FDA-CBER-2021-5683-0396247-0396248_125742_S1_M5_bnt162-01-S-D-ta.xpt,0.02,xpt,,01092022
FDA-CBER-2021-5683-0396234-0396238_125742_S1_M5_bnt162-01-S-D-suppdv.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01092022/FDA-CBER-2021-5683-0396234-0396238_125742_S1_M5_bnt162-01-S-D-suppdv.xpt,0.05,xpt,,01092022
FDA-CBER-2021-5683-0396200-0396213_125742_S1_M5_bnt162-01-A-D-adae.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01092022/FDA-CBER-2021-5683-0396200-0396213_125742_S1_M5_bnt162-01-A-D-adae.xpt,0.79,xpt,,01092022
FDA-CBER-2021-5683-0396223-0396227_125742_S1_M5_bnt162-01-S-D-dv.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01092022/FDA-CBER-2021-5683-0396223-0396227_125742_S1_M5_bnt162-01-S-D-dv.xpt,0.07,xpt,,01092022
FDA-CBER-2021-5683-0396214-0396222_125742_S1_M5_bnt162-01-S-D-cm.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01092022/FDA-CBER-2021-5683-0396214-0396222_125742_S1_M5_bnt162-01-S-D-cm.xpt,0.2,xpt,,01092022
CRFs-for-site-1128.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13012022/CRFs-for-site-1128.pdf,13.55,pdf,3452.0,13012022
Pages-42-289-Section-5.2-listing-clinical-sites-cvs_Part-B.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01122021/Pages-42-289-Section-5.2-listing-clinical-sites-cvs_Part-B.pdf,13.78,pdf,124.0,01122021
Pages-42-289-Section-5.2-listing-clinical-sites-cvs_Part-A.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01122021/Pages-42-289-Section-5.2-listing-clinical-sites-cvs_Part-A.pdf,12.29,pdf,124.0,01122021
CRFs-for-site-1081.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_30122021/CRFs-for-site-1081.pdf,13.2,pdf,3380.0,30122021
125742_S1_M1_priority-review-request.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_24032022/125742_S1_M1_priority-review-request.pdf,2.37,pdf,17.0,24032022
FDA-CBER-2021-5683-0058316 to -0058458_125742_S1_M5_c4591001-A-Supp-define.xml,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0058316 to -0058458_125742_S1_M5_c4591001-A-Supp-define.xml,0.68,xml,,02052022
FDA-CBER-2021-5683-0059000 to -0065773_125742_S1_M5_c4591001-A-D-adcevd.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0059000 to -0065773_125742_S1_M5_c4591001-A-D-adcevd.xpt,394.37,xpt,,02052022
FDA-CBER-2021-5683-0123168 to -0126026_125742_S1_M5_c4591001-A-D-adva.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0123168 to -0126026_125742_S1_M5_c4591001-A-D-adva.xpt,162.85,xpt,,02052022
125742_S1_M5_5351_bnt162-01-interim3-compliance.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-compliance.pdf,7.44,pdf,484.0,02052022
125742_S1_M5_5351_c4591001-interim-mth6-sponsor-signature.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_c4591001-interim-mth6-sponsor-signature.pdf,11.95,pdf,3.0,02052022
125742_S1_M5_CRF_c4591001-1006-10061020.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1006-10061020.pdf,1.52,pdf,187.0,02052022
125742_S1_M5_CRF_c4591001-1001-10011100.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1001-10011100.pdf,2.13,pdf,313.0,02052022
125742_S1_M5_CRF_c4591001-1003-10031197.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1003-10031197.pdf,1.48,pdf,170.0,02052022
125742_S1_M5_bnt162-01-S-csdrg.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_bnt162-01-S-csdrg.pdf,1.2,pdf,73.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-sap.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-sap.pdf,2.91,pdf,35.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-invest-signature.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-invest-signature.pdf,0.62,pdf,1.0,02052022
125742_S1_M5_CRF_c4591001-1003-10031186.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1003-10031186.pdf,2.42,pdf,473.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-notes-for-reader.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-notes-for-reader.pdf,1.21,pdf,3.0,02052022
FDA-CBER-2021-5683-0058676 to -0058794_125742_S1_M5_bnt162-01-A-define.xml,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0058676 to -0058794_125742_S1_M5_bnt162-01-A-define.xml,0.81,xml,,02052022
FDA-CBER-2021-5683-0058795 to -0058828_125742_S1_M5_bnt162-01-A-define-2-0-0.xsl,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0058795 to -0058828_125742_S1_M5_bnt162-01-A-define-2-0-0.xsl,0.18,xsl,,02052022
125742_S1_M5_5351_bnt162-01_20242.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01_20242.pdf,1.66,pdf,100.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-synopsis.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-synopsis.pdf,3.71,pdf,20.0,02052022
125742_S1_M5_c4591001-S-Supp-acrf.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_c4591001-S-Supp-acrf.pdf,2.89,pdf,131.0,02052022
125742_S1_M5_CRF_c4591001-1005-10051214.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1005-10051214.pdf,1.38,pdf,166.0,02052022
125742_S1_M5_CRF_c4591001-1006-10061094.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1006-10061094.pdf,2.08,pdf,249.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-sponsor-personnel-list.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-sponsor-personnel-list.pdf,1.97,pdf,1.0,02052022
125742_S1_M5_CRF_c4591001-1005-10051411.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1005-10051411.pdf,1.35,pdf,157.0,02052022
125742_S1_M5_CRF_c4591001-1006-10061040.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1006-10061040.pdf,3.82,pdf,507.0,02052022
125742_S1_M5_5351_c4591001-interim-mth6-sample-crf.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_c4591001-interim-mth6-sample-crf.pdf,5.39,pdf,225.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-investigators.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-investigators.pdf,6.28,pdf,13.0,02052022
FDA-CBER-2021-5683-0058829 to -0058954_125742_S1_M5_bnt162-01-S-define.xml,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0058829 to -0058954_125742_S1_M5_bnt162-01-S-define.xml,0.96,xml,,02052022
FDA-CBER-2021-5683-0065774 to -0066700_125742_S1_M5_c4591001-A-D-addv.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0065774 to -0066700_125742_S1_M5_c4591001-A-D-addv.xpt,43.54,xpt,,02052022
125742_S1_M5_5351_bnt162-01-interim3-excluded-patients.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-excluded-patients.pdf,2.01,pdf,4.0,02052022
125742_S1_M5_5351_c4591001-interim-mth6-randomization-sensitive.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_c4591001-interim-mth6-randomization-sensitive.pdf,64.92,pdf,4376.0,02052022
125742_S1_M5_CRF_c4591001-1006-10061052.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1006-10061052.pdf,2.12,pdf,259.0,02052022
FDA-CBER-2021-5683-0058955 to -0058999_125742_S1_M5_bnt162-01-S-define-2-0-0.xsl,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0058955 to -0058999_125742_S1_M5_bnt162-01-S-define-2-0-0.xsl,0.18,xsl,,02052022
FDA-CBER-2021-5683-0058479 to -0058594_125742_S1_M5_c4591001-S-define.xml,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0058479 to -0058594_125742_S1_M5_c4591001-S-define.xml,0.88,xml,,02052022
125742_S1_M5_5351_bnt162-01-interim3-sponsor-signature.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-sponsor-signature.pdf,1.52,pdf,2.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-protocol-deviations.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-protocol-deviations.pdf,1.47,pdf,30.0,02052022
125742_S1_M5_CRF_c4591001-1003-10031113.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1003-10031113.pdf,3.22,pdf,409.0,02052022
125742_S1_M5_CRF_c4591001-1005-10051347.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1005-10051347.pdf,1.45,pdf,180.0,02052022
FDA-CBER-2021-5683-0066701 to -0123167_125742_S1_M5_c4591001-A-D-adfacevd.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0066701 to -0123167_125742_S1_M5_c4591001-A-D-adfacevd.xpt,3946.23,xpt,,02052022
125742_S1_M5_5351_bnt162-01_10075.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01_10075.pdf,1.59,pdf,94.0,02052022
125742_S1_M5_CRF_c4591001-1005-10051387.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1005-10051387.pdf,1.69,pdf,202.0,02052022
125742_S1_M5_5351_bnt162-01_20215.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01_20215.pdf,1.63,pdf,97.0,02052022
125742_S1_M5_CRF_c4591001-1003-10031065.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1003-10031065.pdf,2.66,pdf,407.0,02052022
125742_S1_M5_CRF_c4591001-1006-10061098.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1006-10061098.pdf,1.57,pdf,226.0,02052022
125742_S1_M5_c4591001-S-csdrg.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_c4591001-S-csdrg.pdf,1.43,pdf,86.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-protocol.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-protocol.pdf,10.46,pdf,338.0,02052022
125742_S1_M5_CRF_c4591001-1003-10031111.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1003-10031111.pdf,1.71,pdf,202.0,02052022
125742_S1_M5_CRF_c4591001-1005-10051054.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1005-10051054.pdf,1.88,pdf,212.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-discontinued-patients.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-discontinued-patients.pdf,1.99,pdf,2.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-adverse-events.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-adverse-events.pdf,7.08,pdf,338.0,02052022
FDA-CBER-2021-5683-0058615 to -0058652_125742_S1_M5_c4591001-S-Supp-define.xml,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0058615 to -0058652_125742_S1_M5_c4591001-S-Supp-define.xml,0.29,xml,,02052022
FDA-CBER-2021-5683-0058653 to -0058675_125742_S1_M5_c4591001-S-Supp-define-2-0-0.xsl,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0058653 to -0058675_125742_S1_M5_c4591001-S-Supp-define-2-0-0.xsl,0.18,xsl,,02052022
125742_S1_M5_CRF_c4591001-1001-10011135.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1001-10011135.pdf,1.42,pdf,174.0,02052022
125742_S1_M5_5351_bnt162-01_10010.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01_10010.pdf,1.46,pdf,75.0,02052022
125742_S1_M5_CRF_c4591001-1005-10051069.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1005-10051069.pdf,1.46,pdf,193.0,02052022
125742_S1_M5_CRF_c4591001-1003-10031149.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1003-10031149.pdf,1.63,pdf,213.0,02052022
125742_S1_M5_CRF_c4591001-1006-10061176.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1006-10061176.pdf,2.63,pdf,288.0,02052022
125742_S1_M5_bnt162-01-A-adrg.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_bnt162-01-A-adrg.pdf,0.87,pdf,33.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-iec-irb.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-iec-irb.pdf,1.09,pdf,1.0,02052022
125742_S1_M5_c4591001-S-acrf.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_c4591001-S-acrf.pdf,2.89,pdf,131.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-patient-batches.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-patient-batches.pdf,2.56,pdf,18.0,02052022
125742_S1_M5_CRF_c4591001-1005-10051293.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1005-10051293.pdf,2.41,pdf,334.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-sample-crf.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-sample-crf.pdf,9.1,pdf,139.0,02052022
125742_S1_M5_CRF_c4591001-1003-10031038.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1003-10031038.pdf,2.71,pdf,457.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-lab-measurements.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-lab-measurements.pdf,91.06,pdf,7040.0,02052022
125742_S1_M5_CRF_c4591001-1003-10031207.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1003-10031207.pdf,1.44,pdf,174.0,02052022
125742_S1_M5_bnt162-01-S-acrf.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_bnt162-01-S-acrf.pdf,1.4,pdf,41.0,02052022
125742_S1_M5_5351_bnt162-01_20116.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01_20116.pdf,1.51,pdf,81.0,02052022
125742_S1_M5_CRF_c4591001-1005-10051047.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1005-10051047.pdf,1.39,pdf,164.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-demographics.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-demographics.pdf,2.33,pdf,59.0,02052022
125742_S1_M5_5351_bnt162-01-interim3-report-body.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_5351_bnt162-01-interim3-report-body.pdf,41.63,pdf,2151.0,02052022
FDA-CBER-2021-5683-0058459 to -0058478_125742_S1_M5_c4591001-A-Supp-define-2-0-0.xsl,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0058459 to -0058478_125742_S1_M5_c4591001-A-Supp-define-2-0-0.xsl,0.18,xsl,,02052022
FDA-CBER-2021-5683-0058595 to -0058614_125742_S1_M5_c4591001-S-define-2-0-0.xsl,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/FDA-CBER-2021-5683-0058595 to -0058614_125742_S1_M5_c4591001-S-define-2-0-0.xsl,0.18,xsl,,02052022
125742_S1_M5_CRF_c4591001-1001-10011093.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_02052022/125742_S1_M5_CRF_c4591001-1001-10011093.pdf,2.62,pdf,424.0,02052022
125742_S1_M2_27_literature-references.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M2_27_literature-references.pdf,1.75,pdf,2.0,01032022
FDA-CBER-2021-5683-0023926_125742_S1_M5_c4591001-A-report-cci-dementia.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023926_125742_S1_M5_c4591001-A-report-cci-dementia.xlsx,0.01,xlsx,,01032022
125742_S1_M1_priority-review-request.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_priority-review-request.pdf,1.59,pdf,104.0,01032022
FDA-CBER-2021-5683-0022618 to -0022691_125742_S1_M5_c4591001-A-P-adsl-demo-7d-eval-eff-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022618 to -0022691_125742_S1_M5_c4591001-A-P-adsl-demo-7d-eval-eff-sas.txt,0.07,txt,,01032022
125742_S1_M5_c4591001-A-report-cci-lymphoma.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-lymphoma.pdf,0.63,pdf,6.0,01032022
125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.pdf,0.61,pdf,1.0,01032022
125742_S1_M5_CRF_c4591001-1085-10851129.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_CRF_c4591001-1085-10851129.pdf,1.94,pdf,358.0,01032022
FDA-CBER-2021-5683-0023960_125742_S1_M5_c4591001-A-report-cci-mi.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023960_125742_S1_M5_c4591001-A-report-cci-mi.xlsx,0.01,xlsx,,01032022
125742_S1_M1_financial-cert-bias.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_financial-cert-bias.pdf,0.68,pdf,3.0,01032022
FDA-CBER-2021-5683-0023979 to -0023980_125742_S1_M5_c4591001-A-report-cci-renal.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023979 to -0023980_125742_S1_M5_c4591001-A-report-cci-renal.xlsx,0.01,xlsx,,01032022
125742_S1_M5_5351_c4591001-fa-interim-efficacy-response.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-fa-interim-efficacy-response.pdf,2.39,pdf,63.0,01032022
125742_S1_M5_c4591001-T-S-updated-reacto-tlf.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-T-S-updated-reacto-tlf.pdf,17.43,pdf,180.0,01032022
FDA-CBER-2021-5683-0021964 to -0021980_125742_S1_M5_c4591001-A-P-adae-vax-tier2-p3-saf-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0021964 to -0021980_125742_S1_M5_c4591001-A-P-adae-vax-tier2-p3-saf-sas.txt,0.02,txt,,01032022
FDA-CBER-2021-5683-0023500 to -0023507_125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023500 to -0023507_125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.xlsx,0.03,xlsx,,01032022
125742_S1_M1_cover.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_cover.pdf,1.32,pdf,6.0,01032022
125742_S1_M5_c4591001-A-report-cci-rheumatic.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-rheumatic.pdf,0.61,pdf,2.0,01032022
125742_S1_M5_CRF_c4591001-1085-10851116.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_CRF_c4591001-1085-10851116.pdf,1.19,pdf,143.0,01032022
125742_S1_M1_userfee.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_userfee.pdf,0.61,pdf,2.0,01032022
125742_S1_M2_26_pharmkin-written-summary.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M2_26_pharmkin-written-summary.pdf,1.43,pdf,10.0,01032022
FDA-CBER-2021-5683-0023983 to -0023984_125742_S1_M5_c4591001-A-report-cci-rheumatic.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023983 to -0023984_125742_S1_M5_c4591001-A-report-cci-rheumatic.xlsx,0.02,xlsx,,01032022
125742_S1_M5_c4591001-T-S-suppl-arg.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-T-S-suppl-arg.pdf,0.72,pdf,3.0,01032022
125742_S1_M5_5351_c4591001-fa-interim-oversight-committees.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-fa-interim-oversight-committees.pdf,2.29,pdf,60.0,01032022
125742_S1_M5_5351_c4591001-ad-hoc-label-tables.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-ad-hoc-label-tables.pdf,0.87,pdf,14.0,01032022
FDA-CBER-2021-5683-0022063 to -0022135_125742_S1_M5_c4591001-A-P-adce-s010-lr-p3-saf-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022063 to -0022135_125742_S1_M5_c4591001-A-P-adce-s010-lr-p3-saf-sas.txt,0.07,txt,,01032022
125742_S1_M1_ipsp-agreed-letter.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_ipsp-agreed-letter.pdf,0.64,pdf,2.0,01032022
FDA-CBER-2021-5683-0022766 to -0022792_125742_S1_M5_c4591001-A-P-adsl-fu-d2-p3-saf-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022766 to -0022792_125742_S1_M5_c4591001-A-P-adsl-fu-d2-p3-saf-sas.txt,0.03,txt,,01032022
FDA-CBER-2021-5683-0023711 to -0023875_125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023711 to -0023875_125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.xlsx,0.08,xlsx,,01032022
125742_S1_M1_356h.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_356h.pdf,0.7,pdf,6.0,01032022
125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.pdf,0.59,pdf,2.0,01032022
FDA-CBER-2021-5683-0023932_125742_S1_M5_c4591001-A-report-cci-hemiplegia.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023932_125742_S1_M5_c4591001-A-report-cci-hemiplegia.xlsx,0.01,xlsx,,01032022
125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.pdf,0.62,pdf,8.0,01032022
FDA-CBER-2021-5683-0022041 to -0022053_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-wo-sg-eval-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022041 to -0022053_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-wo-sg-eval-sas.txt,0.02,txt,,01032022
FDA-CBER-2021-5683-0022365 to -0022560_125742_S1_M5_c4591001-A-P-adds-s002-all-p3-rand-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022365 to -0022560_125742_S1_M5_c4591001-A-P-adds-s002-all-p3-rand-sas.txt,0.15,txt,,01032022
FDA-CBER-2021-5683-0022601 to -0022617_125742_S1_M5_c4591001-A-P-admh-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022601 to -0022617_125742_S1_M5_c4591001-A-P-admh-sas.txt,0.02,txt,,01032022
FDA-CBER-2021-5683-0023919 to -0023921_125742_S1_M5_c4591001-A-report-cci-cerebrovascular.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023919 to -0023921_125742_S1_M5_c4591001-A-report-cci-cerebrovascular.xlsx,0.01,xlsx,,01032022
FDA-CBER-2021-5683-0023878_125742_S1_M5_c4591001-A-report-cci-aids-hiv.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023878_125742_S1_M5_c4591001-A-report-cci-aids-hiv.xlsx,0.02,xlsx,,01032022
125742_S1_M5_c4591001-A-bmi-12-15-scale.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-bmi-12-15-scale.pdf,0.61,pdf,3.0,01032022
FDA-CBER-2021-5683-0022326 to -0022345_125742_S1_M5_c4591001-A-P-adcevd-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022326 to -0022345_125742_S1_M5_c4591001-A-P-adcevd-sas.txt,0.03,txt,,01032022
125742_S1_M1_us-agent-authorization.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_us-agent-authorization.pdf,1.03,pdf,2.0,01032022
125742_S1_M5_c4591001-T-S-roadmap.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-T-S-roadmap.pdf,0.69,pdf,4.0,01032022
125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.pdf,0.83,pdf,141.0,01032022
125742_S1_M5_5351_c4591001-fa-interim-compliance.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-fa-interim-compliance.pdf,2.04,pdf,49.0,01032022
125742_S1_M5_c4591001-A-report-cci-aids-hiv.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-aids-hiv.pdf,0.61,pdf,2.0,01032022
FDA-CBER-2021-5683-0021888 to -0021901_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf1-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0021888 to -0021901_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf1-sas.txt,0.01,txt,,01032022
FDA-CBER-2021-5683-0023150 to -0023454_125742_S1_M5_c4591001-A-define.xml,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023150 to -0023454_125742_S1_M5_c4591001-A-define.xml,1.37,xml,,01032022
125742_S1_M5_c4591001-A-report-cci-dementia.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-dementia.pdf,0.61,pdf,1.0,01032022
125742_S1_M5_c4591001-A-report-cci-renal.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-renal.pdf,0.61,pdf,2.0,01032022
125742_S1_M5_c4591001-A-comorbidity-categories.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-comorbidity-categories.pdf,0.62,pdf,1.0,01032022
125742_S1_M5_CRF_c4591001-1085-10851216.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_CRF_c4591001-1085-10851216.pdf,1.22,pdf,156.0,01032022
125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.pdf,0.61,pdf,15.0,01032022
FDA-CBER-2021-5683-0023550 to -0023569_125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023550 to -0023569_125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.xlsx,0.02,xlsx,,01032022
125742_S1_M5_c4591001-A-report-cci-mi.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-mi.pdf,0.61,pdf,1.0,01032022
125742_S1_M1_financial-cert-3454.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_financial-cert-3454.pdf,3.44,pdf,81.0,01032022
125742_S1_M4_4223_R-20-0072.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M4_4223_R-20-0072.pdf,5.21,pdf,37.0,01032022
FDA-CBER-2021-5683-0023523 to -0023538_125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023523 to -0023538_125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.xlsx,0.02,xlsx,,01032022
FDA-CBER-2021-5683-0023987_125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023987_125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.xlsx,0.02,xlsx,,01032022
FDA-CBER-2021-5683-0022867 to -0023006_125742_S1_M5_c4591001-A-P-adsl-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022867 to -0023006_125742_S1_M5_c4591001-A-P-adsl-sas.txt,0.19,txt,,01032022
125742_S1_M5_5351_c4591001-fa-interim-excluded-patients-sensitive.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-fa-interim-excluded-patients-sensitive.pdf,15.7,pdf,1448.0,01032022
125742_S1_M5_c4591001-A-report-cci-leukemia.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-leukemia.pdf,0.62,pdf,3.0,01032022
125742_S1_M5_c4591001-A-report-cci-any-malignancy.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-any-malignancy.pdf,0.65,pdf,16.0,01032022
FDA-CBER-2021-5683-0023971 to -0023972_125742_S1_M5_c4591001-A-report-cci-periph-vasc.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023971 to -0023972_125742_S1_M5_c4591001-A-report-cci-periph-vasc.xlsx,0.01,xlsx,,01032022
FDA-CBER-2021-5683-0023955 to -0023958_125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023955 to -0023958_125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.xlsx,0.01,xlsx,,01032022
125742_S1_M5_5351_c4591001-fa-interim-excluded-patients.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-fa-interim-excluded-patients.pdf,1.81,pdf,13.0,01032022
125742_S1_M5_c4591001-A-report-cci-periph-vasc.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-periph-vasc.pdf,0.62,pdf,3.0,01032022
125742_S1_M5_c4591001-T-S-summary-differences-csr-vs-update.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-T-S-summary-differences-csr-vs-update.pdf,0.65,pdf,3.0,01032022
125742_S1_M5_c4591001-A-report-cci-chf.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-chf.pdf,0.61,pdf,2.0,01032022
125742_S1_M5_5351_c4591001-interim-mth6-protocol.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-interim-mth6-protocol.pdf,36.94,pdf,2346.0,01032022
125742_S1_M5_5351_c4591001-interim-mth6-oversight-committees.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-interim-mth6-oversight-committees.pdf,13.0,pdf,61.0,01032022
FDA-CBER-2021-5683-0023936 to -0023937_125742_S1_M5_c4591001-A-report-cci-leukemia.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023936 to -0023937_125742_S1_M5_c4591001-A-report-cci-leukemia.xlsx,0.01,xlsx,,01032022
125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.pdf,0.61,pdf,1.0,01032022
125742_S1_M5_5351_c4591001-fa-interim-lab-measurements-sensitive.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-fa-interim-lab-measurements-sensitive.pdf,4.78,pdf,217.0,01032022
125742_S1_M4_4223_185350.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M4_4223_185350.pdf,1.4,pdf,77.0,01032022
125742_S1_M1_3674.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_3674.pdf,5.12,pdf,2.0,01032022
125742_S1_M2_22_introduction.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M2_22_introduction.pdf,0.65,pdf,2.0,01032022
FDA-CBER-2021-5683-0023540_125742_S1_M5_c4591001-A-comorbidity-categories.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023540_125742_S1_M5_c4591001-A-comorbidity-categories.xlsx,0.02,xlsx,,01032022
125742_S1_M2_27_synopses-indiv-studies.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M2_27_synopses-indiv-studies.pdf,1.75,pdf,2.0,01032022
125742_S1_M2_24_nonclinical-overview.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M2_24_nonclinical-overview.pdf,1.61,pdf,36.0,01032022
125742_S1_M5_c4591001-A-report-cci-cerebrovascular.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-cerebrovascular.pdf,0.62,pdf,3.0,01032022
FDA-CBER-2021-5683-0023930_125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023930_125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.xlsx,0.01,xlsx,,01032022
FDA-CBER-2021-5683-0022028 to -0022040_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-sg-eval-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022028 to -0022040_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-sg-eval-sas.txt,0.02,txt,,01032022
FDA-CBER-2021-5683-0023490 to -0023491_125742_S1_M5_c4591001-A-bmi-12-15-scale.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023490 to -0023491_125742_S1_M5_c4591001-A-bmi-12-15-scale.xlsx,0.01,xlsx,,01032022
FDA-CBER-2021-5683-0023965_125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023965_125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.xlsx,0.01,xlsx,,01032022
FDA-CBER-2021-5683-0023924_125742_S1_M5_c4591001-A-report-cci-chf.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023924_125742_S1_M5_c4591001-A-report-cci-chf.xlsx,0.01,xlsx,,01032022
FDA-CBER-2021-5683-0021916 to -0021929_125742_S1_M5_c4591001-A-P-adae-s092-all-unb-p3-saf-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0021916 to -0021929_125742_S1_M5_c4591001-A-P-adae-s092-all-unb-p3-saf-sas.txt,0.01,txt,,01032022
125742_S1_M1_fast-track-designation.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_fast-track-designation.pdf,0.63,pdf,2.0,01032022
FDA-CBER-2021-5683-0022136 to -0022325_125742_S1_M5_c4591001-A-P-adce-s020-se-p3-saf-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022136 to -0022325_125742_S1_M5_c4591001-A-P-adce-s020-se-p3-saf-sas.txt,0.19,txt,,01032022
125742_S1_M5_5351_c4591001-fa-interim-lab-measurements.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-fa-interim-lab-measurements.pdf,12.02,pdf,671.0,01032022
FDA-CBER-2021-5683-0023967_125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023967_125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.xlsx,0.01,xlsx,,01032022
FDA-CBER-2021-5683-0022054 to -0022062_125742_S1_M5_c4591001-A-P-adc19ef-ve-sev-cov-pd1-aai-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022054 to -0022062_125742_S1_M5_c4591001-A-P-adc19ef-ve-sev-cov-pd1-aai-sas.txt,0.01,txt,,01032022
125742_S1_M5_5351_c4591001-fa-interim-compliance-sensitive.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-fa-interim-compliance-sensitive.pdf,1.26,pdf,3.0,01032022
125742_S1_M5_CRF_c4591001-1085-10851018.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_CRF_c4591001-1085-10851018.pdf,2.25,pdf,423.0,01032022
125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.pdf,0.62,pdf,4.0,01032022
FDA-CBER-2021-5683-0022568 to -0022600_125742_S1_M5_c4591001-A-P-adfacevd-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022568 to -0022600_125742_S1_M5_c4591001-A-P-adfacevd-sas.txt,0.05,txt,,01032022
FDA-CBER-2021-5683-0022692 to -0022765_125742_S1_M5_c4591001-A-P-adsl-demo-7d-wwo-eval-eff-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022692 to -0022765_125742_S1_M5_c4591001-A-P-adsl-demo-7d-wwo-eval-eff-sas.txt,0.07,txt,,01032022
FDA-CBER-2021-5683-0022793 to -0022866_125742_S1_M5_c4591001-A-P-adsl-s005-demo-all-p3-saf-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022793 to -0022866_125742_S1_M5_c4591001-A-P-adsl-s005-demo-all-p3-saf-sas.txt,0.07,txt,,01032022
125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.pdf,0.61,pdf,1.0,01032022
125742_S1_M5_5351_c4591001-fa-interim-errata.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-fa-interim-errata.pdf,2.27,pdf,1.0,01032022
125742_S1_M1_waiver-req-designated-suffix.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_waiver-req-designated-suffix.pdf,2.74,pdf,4.0,01032022
FDA-CBER-2021-5683-0023963_125742_S1_M5_c4591001-A-report-cci-mild-liver.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023963_125742_S1_M5_c4591001-A-report-cci-mild-liver.xlsx,0.01,xlsx,,01032022
125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.pdf,0.61,pdf,1.0,01032022
FDA-CBER-2021-5683-0023944 to -0023950_125742_S1_M5_c4591001-A-report-cci-lymphoma.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023944 to -0023950_125742_S1_M5_c4591001-A-report-cci-lymphoma.xlsx,0.02,xlsx,,01032022
125742_S1_M1_debarment.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_debarment.pdf,0.64,pdf,1.0,01032022
FDA-CBER-2021-5683-0021944 to -0021963_125742_S1_M5_c4591001-A-P-adae-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0021944 to -0021963_125742_S1_M5_c4591001-A-P-adae-sas.txt,0.03,txt,,01032022
125742_S1_M5_c4591001-A-report-cci-hemiplegia.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-hemiplegia.pdf,0.61,pdf,1.0,01032022
FDA-CBER-2021-5683-0023455 to -0023486_125742_S1_M5_c4591001-A-define-2-0-0.xsl,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023455 to -0023486_125742_S1_M5_c4591001-A-define-2-0-0.xsl,0.18,xsl,,01032022
125742_S1_M5_c4591001-A-adrg.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-adrg.pdf,1.54,pdf,84.0,01032022
125742_S1_M5_c4591001-T-S-final-reacto-tables-track.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-T-S-final-reacto-tables-track.pdf,2.22,pdf,104.0,01032022
FDA-CBER-2021-5683-0021981 to -0022027_125742_S1_M5_c4591001-A-P-adc19ef-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0021981 to -0022027_125742_S1_M5_c4591001-A-P-adc19ef-sas.txt,0.08,txt,,01032022
FDA-CBER-2021-5683-0021930 to -0021943_125742_S1_M5_c4591001-A-P-adae-s092-cr-cut-p3x-saf-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0021930 to -0021943_125742_S1_M5_c4591001-A-P-adae-s092-cr-cut-p3x-saf-sas.txt,0.01,txt,,01032022
125742_S1_M5_c4591001-A-report-cci-pulmonary.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-pulmonary.pdf,0.61,pdf,2.0,01032022
125742_S1_M1_trans-of-oblig.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_trans-of-oblig.pdf,0.7,pdf,2.0,01032022
FDA-CBER-2021-5683-0022346 to -0022364_125742_S1_M5_c4591001-A-P-adcm-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022346 to -0022364_125742_S1_M5_c4591001-A-P-adcm-sas.txt,0.03,txt,,01032022
FDA-CBER-2021-5683-0023928_125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023928_125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.xlsx,0.01,xlsx,,01032022
125742_S1_M2_26_pharmkin-tabulated-summary.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M2_26_pharmkin-tabulated-summary.pdf,1.34,pdf,14.0,01032022
125742_S1_M1_exclusivity-claim.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M1_exclusivity-claim.pdf,0.6,pdf,1.0,01032022
FDA-CBER-2021-5683-0021902 to -0021915_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf2-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0021902 to -0021915_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf2-sas.txt,0.01,txt,,01032022
FDA-CBER-2021-5683-0022561 to -0022567_125742_S1_M5_c4591001-A-P-adds-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0022561 to -0022567_125742_S1_M5_c4591001-A-P-adds-sas.txt,0.01,txt,,01032022
125742_S1_M5_5351_c4591001-fa-interim-protocol.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_5351_c4591001-fa-interim-protocol.pdf,31.31,pdf,1413.0,01032022
125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.pdf,0.59,pdf,9.0,01032022
FDA-CBER-2021-5683-0023895 to -0023915_125742_S1_M5_c4591001-A-report-cci-any-malignancy.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023895 to -0023915_125742_S1_M5_c4591001-A-report-cci-any-malignancy.xlsx,0.03,xlsx,,01032022
FDA-CBER-2021-5683-0023032 to -0023065_125742_S1_M5_c4591001-A-P-adva-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023032 to -0023065_125742_S1_M5_c4591001-A-P-adva-sas.txt,0.04,txt,,01032022
FDA-CBER-2021-5683-0023975 to -0023976_125742_S1_M5_c4591001-A-report-cci-pulmonary.xlsx,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023975 to -0023976_125742_S1_M5_c4591001-A-report-cci-pulmonary.xlsx,0.01,xlsx,,01032022
125742_S1_M5_c4591001-A-report-cci-mild-liver.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_c4591001-A-report-cci-mild-liver.pdf,0.61,pdf,2.0,01032022
125742_S1_M5_CRF_c4591001-1085-10851246.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/125742_S1_M5_CRF_c4591001-1085-10851246.pdf,1.14,pdf,158.0,01032022
FDA-CBER-2021-5683-0023007 to -0023031_125742_S1_M5_c4591001-A-P-adsympt-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01032022/FDA-CBER-2021-5683-0023007 to -0023031_125742_S1_M5_c4591001-A-P-adsympt-sas.txt,0.04,txt,,01032022
056-ORDER-GRANTING-IN-PART-THE-MOTION-TO-MODIFY-THE-PRODUCTION-SCHEDULE-AND-ADDOPTS-THE-JOINT-STATUS-REPORT-MODIFIED-AGREED-PRODUCTION-SCHEDULE.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/056-ORDER-GRANTING-IN-PART-THE-MOTION-TO-MODIFY-THE-PRODUCTION-SCHEDULE-AND-ADDOPTS-THE-JOINT-STATUS-REPORT-MODIFIED-AGREED-PRODUCTION-SCHEDULE.pdf,0.12,pdf,2.0,
037-Brief-Memorandum-in-Support-filed-by-FDA-re-36-MOTION-To-Partially-Modify-Scheduling-Order-1.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/037-Brief-Memorandum-in-Support-filed-by-FDA-re-36-MOTION-To-Partially-Modify-Scheduling-Order-1.pdf,0.24,pdf,12.0,
030-FDAs-Appendix-in-Support-of-Brief.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/030-FDAs-Appendix-in-Support-of-Brief.pdf,1.5,pdf,36.0,
023-FDA-Appendix-in-Support-1.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/023-FDA-Appendix-in-Support-1.pdf,8.79,pdf,110.0,
031-REPLY-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-22-Brief-Memorandum-in-Support-of-Motion.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/031-REPLY-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-22-Brief-Memorandum-in-Support-of-Motion.pdf,0.17,pdf,26.0,
041-Memorandum-in-Support-filed-by-Pfizer-Inc.-re-40-MOTION-to-Intervene-for-a-Limited-Purpose.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/041-Memorandum-in-Support-filed-by-Pfizer-Inc.-re-40-MOTION-to-Intervene-for-a-Limited-Purpose.pdf,0.99,pdf,16.0,
038-Appendix-in-Support-filed-by-FDA-re-36-MOTION-To-Partially-Modify-Scheduling-Order.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/038-Appendix-in-Support-filed-by-FDA-re-36-MOTION-To-Partially-Modify-Scheduling-Order.pdf,1.14,pdf,19.0,
032-Appendix-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-31-Reply.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/032-Appendix-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-31-Reply.pdf,23.71,pdf,150.0,
022-FDA-Brief-in-Advance-of-Scheduling-Conference.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/022-FDA-Brief-in-Advance-of-Scheduling-Conference.pdf,0.27,pdf,19.0,
Order-February-7-2022.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/Order-February-7-2022.pdf,0.15,pdf,2.0,
044-PL-PHPMTS-MOL-IN-OPPOSITION-TO-DEFENDANTS-MOTION-TO-MODIFY-THE-SCHEDULING-ORDER-OF-THE-COURT.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/044-PL-PHPMTS-MOL-IN-OPPOSITION-TO-DEFENDANTS-MOTION-TO-MODIFY-THE-SCHEDULING-ORDER-OF-THE-COURT.pdf,0.41,pdf,20.0,
091621-Complaint.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/091621-Complaint.pdf,1.05,pdf,37.0,
111521-Second-Joint-Status-Report.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/111521-Second-Joint-Status-Report.pdf,0.37,pdf,14.0,
027-Appendix-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-26-Brief-Memorandum-in-Support-of-Motion.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/027-Appendix-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-26-Brief-Memorandum-in-Support-of-Motion.pdf,16.41,pdf,633.0,
034-Transcript-of-Scheduling-Conference-December-14-2021.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/034-Transcript-of-Scheduling-Conference-December-14-2021.pdf,0.14,pdf,56.0,
ORDER_2022_01_06.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/ORDER_2022_01_06.pdf,0.17,pdf,4.0,
047-PLAINTIFFS-RESPONSE-TO-PFIZER-INC.S-MOTION-FOR-LEAVE-TO-INTERVENE-FOR-A-LIMITED-PURPOSE.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/047-PLAINTIFFS-RESPONSE-TO-PFIZER-INC.S-MOTION-FOR-LEAVE-TO-INTERVENE-FOR-A-LIMITED-PURPOSE.pdf,0.29,pdf,15.0,
029-FDAs-Reply-re-Brief-in-Support-of-Motion.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/029-FDAs-Reply-re-Brief-in-Support-of-Motion.pdf,0.27,pdf,28.0,
026-Brief-Memorandum-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-21-Order-Setting-DeadlineHearing.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/026-Brief-Memorandum-in-Support-filed-by-Public-Health-and-Medical-Professionals-for-Transparency-re-21-Order-Setting-DeadlineHearing.pdf,0.23,pdf,30.0,
046-RESPONSE-filed-by-Food-and-Drug-Administration-re-40-MOTION-to-Intervene-for-a-Limited-Purpose.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/court_documents/046-RESPONSE-filed-by-Food-and-Drug-Administration-re-40-MOTION-to-Intervene-for-a-Limited-Purpose.pdf,0.13,pdf,4.0,
CRFs-for-site-1096.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_18012022/CRFs-for-site-1096.pdf,11.28,pdf,2937.0,18012022
125742_S1_M5_5351_c4591001-interim-mth6-adverse-events-sensitive.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-interim-mth6-adverse-events-sensitive.pdf,1.2,pdf,3.0,01042022
125742_S1_M5_5351_c4591001-interim-mth6-demographics.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-interim-mth6-demographics.pdf,27.77,pdf,2951.0,01042022
125742_S1_M5_5351_c4591001-fa-interim-publications.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-publications.pdf,9.76,pdf,30.0,01042022
125742_S1_M5_5351_c4591001-fa-interim-iec-irb-consent-form.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-iec-irb-consent-form.pdf,7.56,pdf,265.0,01042022
125742_S1_M5_5351_c4591001-fa-interim-invest-signature.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-invest-signature.pdf,0.66,pdf,1.0,01042022
125742_S1_M5_5351_c4591001-interim-mth6-audit-certificates.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-interim-mth6-audit-certificates.pdf,1.28,pdf,5.0,01042022
reissue_5.3.6 postmarketing experience.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/reissue_5.3.6 postmarketing experience.pdf,0.94,pdf,38.0,01042022
125742_S1_M5_5351_c4591001-fa-interim-sponsor-signature.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-sponsor-signature.pdf,2.31,pdf,3.0,01042022
125742_S1_M5_5351_c4591001-fa-interim-protocol-deviations.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-protocol-deviations.pdf,1.17,pdf,2.0,01042022
125742_S1_M5_5351_c4591001-fa-interim-sample-crf.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-sample-crf.pdf,5.4,pdf,212.0,01042022
125742_S1_M5_5351_c4591001-fa-interim-audit-certificates.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-audit-certificates.pdf,0.85,pdf,4.0,01042022
125742_S1_M5_5351_c4591001-fa-interim-demographics.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-demographics.pdf,27.74,pdf,3139.0,01042022
125742_S1_M5_5351_c4591001-interim-mth6-invest-signature.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-interim-mth6-invest-signature.pdf,1.18,pdf,1.0,01042022
125742_S1_M5_5351_c4591001-fa-interim-randomization-sensitive.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-randomization-sensitive.pdf,59.43,pdf,4412.0,01042022
125742_S1_M5_5351_c4591001-fa-interim-randomization.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01042022/125742_S1_M5_5351_c4591001-fa-interim-randomization.pdf,1.51,pdf,15.0,01042022
FDA-CBER-2021-5683-0593482-0593595-125742_S1_M5_bnt162-01-S-D-pe.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01112022/FDA-CBER-2021-5683-0593482-0593595-125742_S1_M5_bnt162-01-S-D-pe.xpt,1.62,xpt,,01112022
FDA-CBER-2021-5683-0593327-0593481-125742_S1_M5_bnt162-01-S-D-ce.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01112022/FDA-CBER-2021-5683-0593327-0593481-125742_S1_M5_bnt162-01-S-D-ce.xpt,3.87,xpt,,01112022
FDA-CBER-2021-5683-0539816-0593326-125742_S1_M5_c4591001-01-S-Supp-D-face.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01112022/FDA-CBER-2021-5683-0539816-0593326-125742_S1_M5_c4591001-01-S-Supp-D-face.xpt,1420.74,xpt,,01112022
FDA-CBER-2021-5683-0593596-0593620-125742_S1_M5_bnt162-01-S-D-se.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01112022/FDA-CBER-2021-5683-0593596-0593620-125742_S1_M5_bnt162-01-S-D-se.xpt,0.15,xpt,,01112022
FDA-CBER-2021-5683-0593621-0593664-125742_S1_M5_bnt162-01-S-Supp-D-suppae.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01112022/FDA-CBER-2021-5683-0593621-0593664-125742_S1_M5_bnt162-01-S-Supp-D-suppae.xpt,0.14,xpt,,01112022
FDA-CBER-2021-5683-0593665-0593743-125742_S1_M5_bnt162-01-S-Supp-D-suppcm.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01112022/FDA-CBER-2021-5683-0593665-0593743-125742_S1_M5_bnt162-01-S-Supp-D-suppcm.xpt,0.52,xpt,,01112022
FDA-CBER-2021-5683-0593770-0593800-125742_S1_M5_bnt162-01-S-Supp-D-suppec.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01112022/FDA-CBER-2021-5683-0593770-0593800-125742_S1_M5_bnt162-01-S-Supp-D-suppec.xpt,0.25,xpt,,01112022
FDA-CBER-2021-5683-0593801-0593831-125742_S1_M5_bnt162-01-S-Supp-D-suppex.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01112022/FDA-CBER-2021-5683-0593801-0593831-125742_S1_M5_bnt162-01-S-Supp-D-suppex.xpt,0.24,xpt,,01112022
125742_S1_M4_20256434.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01112022/125742_S1_M4_20256434.pdf,21.85,pdf,1145.0,01112022
FDA-CBER-2021-5683-0593744-0593769-125742_S1_M5_bnt162-01-S-Supp-D-suppds.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01112022/FDA-CBER-2021-5683-0593744-0593769-125742_S1_M5_bnt162-01-S-Supp-D-suppds.xpt,0.1,xpt,,01112022
125742_S2_M1_com195lpus-carton-puurs.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_com195lpus-carton-puurs.pdf,0.67,pdf,1.0,01072022
125742_S1_M5_5351_c4591001-interim-mth6-compliance-sensitive.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-compliance-sensitive.pdf,1.2,pdf,2.0,01072022
125742_S2_M1_comvlabkz-vial-kzoo.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_comvlabkz-vial-kzoo.pdf,0.84,pdf,1.0,01072022
125742_S1_M5_5351_c4591001-interim-mth6-adverse-events.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-adverse-events.pdf,183.44,pdf,3645.0,01072022
FDA-CBER-2021-5683-0285644 to -0285651_125742_S1_M5_c4591001-S-D-mo.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/FDA-CBER-2021-5683-0285644 to -0285651_125742_S1_M5_c4591001-S-D-mo.xpt,0.07,xpt,,01072022
125742_S2_M1_comvlabp-vial-puurs.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_comvlabp-vial-puurs.pdf,0.63,pdf,1.0,01072022
125742_S1_M5_5351_c4591001-fa-interim-sap.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-fa-interim-sap.pdf,3.23,pdf,59.0,01072022
FDA-CBER-2021-5683-0286072 to -0286266_125742_S1_M5_c4591001-S-Supp-D-relrec.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/FDA-CBER-2021-5683-0286072 to -0286266_125742_S1_M5_c4591001-S-Supp-D-relrec.xpt,0.55,xpt,,01072022
125742_S1_M5_5351_c4591001-interim-mth6-interlab-standard.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-interlab-standard.pdf,10.87,pdf,1.0,01072022
125742_S2_M1_right-of-reference.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_right-of-reference.pdf,1.73,pdf,1.0,01072022
125742_S2_M1_loa-dmf-031786-vials.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_loa-dmf-031786-vials.pdf,1.95,pdf,1.0,01072022
FDA-CBER-2021-5683-0282366 to -0285643_125742_S1_M5_c4591001-S-D-mb.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/FDA-CBER-2021-5683-0282366 to -0285643_125742_S1_M5_c4591001-S-D-mb.xpt,48.15,xpt,,01072022
125742_S1_M5_5351_c4591001-interim-mth6-lab-measurements-sensitive.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-lab-measurements-sensitive.pdf,5.4,pdf,430.0,01072022
125742_S1_M5_5351_c4591001-interim-mth6-protocol-deviations.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-protocol-deviations.pdf,1.63,pdf,68.0,01072022
125742_S1_M5_5351_c4591001-interim-mth6-excluded-patients-sensitive.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-excluded-patients-sensitive.pdf,2.79,pdf,198.0,01072022
125742_S2_M1_fk-diluent-carton.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_fk-diluent-carton.pdf,0.59,pdf,1.0,01072022
125742_S1_M5_5351_c4591001-interim-mth6-discontinued-patients.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-discontinued-patients.pdf,4.19,pdf,232.0,01072022
125742_S2_M1_hospira-diluent-label.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_hospira-diluent-label.pdf,0.76,pdf,1.0,01072022
125742_S2_M1_loa-dmf-011321-vials.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_loa-dmf-011321-vials.pdf,1.0,pdf,1.0,01072022
125742_S2_M1_loa-dmf-012683-vials.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_loa-dmf-012683-vials.pdf,0.62,pdf,1.0,01072022
125742_S1_M5_5351_c4591001-fa-interim-narrative-sensitive.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-fa-interim-narrative-sensitive.pdf,18.85,pdf,3611.0,01072022
125742_S2_M1_fk-diluent-stamp.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_fk-diluent-stamp.pdf,0.58,pdf,1.0,01072022
FDA-CBER-2021-5683-0225598 to -0282129_125742_S1_M5_c4591001-A-Supp-D-adfacevd.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/FDA-CBER-2021-5683-0225598 to -0282129_125742_S1_M5_c4591001-A-Supp-D-adfacevd.xpt,4043.53,xpt,,01072022
FDA-CBER-2021-5683-0225100 to -0225597_125742_S1_M5_c4591001-A-D-adcm.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/FDA-CBER-2021-5683-0225100 to -0225597_125742_S1_M5_c4591001-A-D-adcm.xpt,46.4,xpt,,01072022
125742_S1_M5_5351_c4591001-interim-mth6-efficacy-response.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-efficacy-response.pdf,1.22,pdf,5.0,01072022
125742_S2_M5_5354_wi235284-protocol.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M5_5354_wi235284-protocol.pdf,15.5,pdf,60.0,01072022
125742_S2_M1_loa-dmf-011793-vials.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_loa-dmf-011793-vials.pdf,0.68,pdf,1.0,01072022
FDA-CBER-2021-5683-0296904 to -0307543_125742_S1_M5_c4591001-S-D-suppce.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/FDA-CBER-2021-5683-0296904 to -0307543_125742_S1_M5_c4591001-S-D-suppce.xpt,53.58,xpt,,01072022
125742_S2_M1_hospira-diluent-carton.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_hospira-diluent-carton.pdf,0.96,pdf,1.0,01072022
FDA-CBER-2021-5683-0282329 to -0282365_125742_S1_M5_c4591001-S-D-ie.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/FDA-CBER-2021-5683-0282329 to -0282365_125742_S1_M5_c4591001-S-D-ie.xpt,0.47,xpt,,01072022
125742_S1_M5_5351_c4591001-interim-mth6-errata.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-errata.pdf,1.8,pdf,2.0,01072022
125742_S2_M1_com195lkz-carton-kzoo.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_com195lkz-carton-kzoo.pdf,1.0,pdf,1.0,01072022
125742_S2_M1_loa-dmf-10953-stopper.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_loa-dmf-10953-stopper.pdf,0.84,pdf,2.0,01072022
125742_S1_M5_5351_c4591001-interim-mth6-sap.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-sap.pdf,5.4,pdf,96.0,01072022
125742_S2_M1_com25ctkz-carton-kzoo.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_com25ctkz-carton-kzoo.pdf,0.62,pdf,1.0,01072022
125742_S2_M1_com25ctpus-carton-puurs.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_com25ctpus-carton-puurs.pdf,0.66,pdf,1.0,01072022
FDA-CBER-2021-5683-0285652 to -0286071_125742_S1_M5_c4591001-S-D-pe.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/FDA-CBER-2021-5683-0285652 to -0286071_125742_S1_M5_c4591001-S-D-pe.xpt,8.89,xpt,,01072022
125742_S1_M5_5351_c4591001-interim-mth6-excluded-patients.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S1_M5_5351_c4591001-interim-mth6-excluded-patients.pdf,1.29,pdf,6.0,01072022
FDA-CBER-2021-5683-0282130 to -0282328_125742_S1_M5_c4591001-S-D-cm.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/FDA-CBER-2021-5683-0282130 to -0282328_125742_S1_M5_c4591001-S-D-cm.xpt,3.99,xpt,,01072022
FDA-CBER-2021-5683-0286267 to -0296903_125742_S1_M5_c4591001-S-Supp-D-suppce.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/FDA-CBER-2021-5683-0286267 to -0296903_125742_S1_M5_c4591001-S-Supp-D-suppce.xpt,83.19,xpt,,01072022
125742_S2_M1_loa-dmf-011820-vials.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01072022/125742_S2_M1_loa-dmf-011820-vials.pdf,0.6,pdf,1.0,01072022
STN-125742_0_0-Section-2.7.3-Summary-of-Clinical-Efficacy.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/STN-125742_0_0-Section-2.7.3-Summary-of-Clinical-Efficacy.pdf,3.15,pdf,182.0,13122021
BATES-FDA-CBER-2021-5683-0002372_adc19ef-ve-cov-7pd2-eval-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/BATES-FDA-CBER-2021-5683-0002372_adc19ef-ve-cov-7pd2-eval-sas.txt,0.01,txt,,13122021
STN-125742_0_0-Section-2.7.4-summary-clin-safety.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/STN-125742_0_0-Section-2.7.4-summary-clin-safety.pdf,6.5,pdf,344.0,13122021
STN-125742_0_0-Section-2.5-Clinical-Overview.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/STN-125742_0_0-Section-2.5-Clinical-Overview.pdf,4.2,pdf,334.0,13122021
BATES-FDA-CBER-2021-5683-0002376_relrec.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/BATES-FDA-CBER-2021-5683-0002376_relrec.xpt,0.55,xpt,,13122021
BATES-FDA-CBER-2021-5683-0002373_adc19ef-ve-sev-cov-7pd2-eval-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/BATES-FDA-CBER-2021-5683-0002373_adc19ef-ve-sev-cov-7pd2-eval-sas.txt,0.01,txt,,13122021
BATES-FDA-CBER-2021-5683-0002377_supppr.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/BATES-FDA-CBER-2021-5683-0002377_supppr.xpt,0.07,xpt,,13122021
BATES-FDA-CBER-2021-5683-0002374_adc19ef-ve-sev-cov-7pd2-wo-eval-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/BATES-FDA-CBER-2021-5683-0002374_adc19ef-ve-sev-cov-7pd2-wo-eval-sas.txt,0.01,txt,,13122021
CRFs-for-site-1055.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/CRFs-for-site-1055.pdf,6.42,pdf,2030.0,13122021
BATES-FDA-CBER-2021-5683-0002379_te.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/BATES-FDA-CBER-2021-5683-0002379_te.xpt,0.0,xpt,,13122021
BATES-FDA-CBER-2021-5683-0002375_addv-sas.txt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/BATES-FDA-CBER-2021-5683-0002375_addv-sas.txt,0.0,txt,,13122021
BATES-FDA-CBER-2021-5683-0002380_ti.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/BATES-FDA-CBER-2021-5683-0002380_ti.xpt,0.04,xpt,,13122021
BATES-FDA-CBER-2021-5683-0002378_ta.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/BATES-FDA-CBER-2021-5683-0002378_ta.xpt,0.01,xpt,,13122021
signed-F21-5683-CBER-Dec-13-2021-Response-Letter.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_13122021/signed-F21-5683-CBER-Dec-13-2021-Response-Letter.pdf,0.2,pdf,2.0,13122021
FDA-CBER-2021-5683-0484461-0537913-125742_S1_M5_c4591001-S-D-face.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_03102022/FDA-CBER-2021-5683-0484461-0537913-125742_S1_M5_c4591001-S-D-face.xpt,1586.43,xpt,,03102022
FDA-CBER-2021-5683-0484452-0484460-125742_S1_M5_bnt162-01-S-D-ti.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_03102022/FDA-CBER-2021-5683-0484452-0484460-125742_S1_M5_bnt162-01-S-D-ti.xpt,0.08,xpt,,03102022
FDA-CBER-2021-5683-0484442-0484451-125742_S1_M5_bnt162-01-S-D-ex.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_03102022/FDA-CBER-2021-5683-0484442-0484451-125742_S1_M5_bnt162-01-S-D-ex.xpt,0.08,xpt,,03102022
FDA-CBER-2021-5683-0537914-0539336-125742_S1_M5_bnt162-01-A-D-adfacevd.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_03102022/FDA-CBER-2021-5683-0537914-0539336-125742_S1_M5_bnt162-01-A-D-adfacevd.xpt,62.61,xpt,,03102022
FDA-CBER-2021-5683-0484356-0484378-125742_S1_M5_bnt162-01-S-D-xa.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_03102022/FDA-CBER-2021-5683-0484356-0484378-125742_S1_M5_bnt162-01-S-D-xa.xpt,0.49,xpt,,03102022
FDA-CBER-2021-5683-0484419-0484441-125742_S1_M5_bnt162-01-S-D-eg.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_03102022/FDA-CBER-2021-5683-0484419-0484441-125742_S1_M5_bnt162-01-S-D-eg.xpt,0.29,xpt,,03102022
FDA-CBER-2021-5683-0484384-0484408-125742_S1_M5_bnt162-01-S-D-ds.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_03102022/FDA-CBER-2021-5683-0484384-0484408-125742_S1_M5_bnt162-01-S-D-ds.xpt,0.17,xpt,,03102022
FDA-CBER-2021-5683-0484342-0484355-125742_S1_M5_bnt162-01-S-D-ae.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_03102022/FDA-CBER-2021-5683-0484342-0484355-125742_S1_M5_bnt162-01-S-D-ae.xpt,0.41,xpt,,03102022
FDA-CBER-2021-5683-0484379-0484383-125742_S1_M5_bnt162-01-S-D-dm.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_03102022/FDA-CBER-2021-5683-0484379-0484383-125742_S1_M5_bnt162-01-S-D-dm.xpt,0.06,xpt,,03102022
FDA-CBER-2021-5683-0539337-0539815-125742_S1_M5_bnt162-01-A-D-advs.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_03102022/FDA-CBER-2021-5683-0539337-0539815-125742_S1_M5_bnt162-01-A-D-advs.xpt,15.83,xpt,,03102022
FDA-CBER-2021-5683-0484409-0484418-125742_S1_M5_bnt162-01-S-D-ec.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_03102022/FDA-CBER-2021-5683-0484409-0484418-125742_S1_M5_bnt162-01-S-D-ec.xpt,0.08,xpt,,03102022
125742_S1_M5_CRF_c4591001-1013-10131165.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131165.pdf,1.3,pdf,191.0,01062022
125742_S1_M5_CRF_c4591001-1015-10151047.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1015-10151047.pdf,1.15,pdf,156.0,01062022
FDA-CBER-2021-5683-0165893 to -0168682_125742_S1_M5_c4591001-S-D-is.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0165893 to -0168682_125742_S1_M5_c4591001-S-D-is.xpt,29.38,xpt,,01062022
125742_S1_M5_CRF_c4591001-1081-10811194 reissue.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1081-10811194 reissue.pdf,1.76,pdf,355.0,01062022
FDA-CBER-2021-5683-0178319 to -0180190_125742_S1_M5_c4591001-S-D-suppho.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0178319 to -0180190_125742_S1_M5_c4591001-S-D-suppho.xpt,8.22,xpt,,01062022
FDA-CBER-2021-5683-0196049 to -0205317_125742_S1_M5_c4591001-S-Supp-D-ce.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0196049 to -0205317_125742_S1_M5_c4591001-S-Supp-D-ce.xpt,361.39,xpt,,01062022
125742_S1_M2_summary-biopharm.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M2_summary-biopharm.pdf,1.74,pdf,3.0,01062022
125742_S1_M5_CRF_c4591001-1008-10081152.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1008-10081152.pdf,1.01,pdf,124.0,01062022
FDA-CBER-2021-5683-0174607 to -0178318_125742_S1_M5_c4591001-S-D-suppdv.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0174607 to -0178318_125742_S1_M5_c4591001-S-D-suppdv.xpt,23.37,xpt,,01062022
125742_S1_M5_CRF_c4591001-1008-10081184.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1008-10081184.pdf,1.18,pdf,146.0,01062022
125742_S1_M5_CRF_c4591001-1013-10131229.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131229.pdf,1.15,pdf,157.0,01062022
125742_S1_M5_CRF_c4591001-1007-10071192.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071192.pdf,1.84,pdf,283.0,01062022
125742_S1_M5_CRF_c4591001-1007-10071347.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071347.pdf,1.45,pdf,181.0,01062022
125742_S1_M5_CRF_c4591001-1015-10151134.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1015-10151134.pdf,1.47,pdf,207.0,01062022
125742_S1_M5_5351_c4591001-interim-mth6-patient-batches.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_5351_c4591001-interim-mth6-patient-batches.pdf,1.34,pdf,158.0,01062022
FDA-CBER-2021-5683-0159487 to -0162689_125742_S1_M5_c4591001-S-D-ec.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0159487 to -0162689_125742_S1_M5_c4591001-S-D-ec.xpt,46.56,xpt,,01062022
125742_S1_M5_CRF_c4591001-1013-10131176.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131176.pdf,2.78,pdf,507.0,01062022
125742_S1_M5_5351_c4591001-fa-interim-discontinued-patients.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_5351_c4591001-fa-interim-discontinued-patients.pdf,2.91,pdf,112.0,01062022
FDA-CBER-2021-5683-0158560 to -0159486_125742_S1_M5_c4591001-S-D-dv.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0158560 to -0159486_125742_S1_M5_c4591001-S-D-dv.xpt,11.43,xpt,,01062022
125742_S1_M5_CRF_c4591001-1012-10121163.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1012-10121163.pdf,1.56,pdf,225.0,01062022
FDA-CBER-2021-5683-0208521 to -0216666_125742_S1_M5_c4591001-S-Supp-D-suppvs.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0208521 to -0216666_125742_S1_M5_c4591001-S-Supp-D-suppvs.xpt,39.16,xpt,,01062022
125742_S1_M5_CRF_c4591001-1007-10071097.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071097.pdf,2.08,pdf,249.0,01062022
FDA-CBER-2021-5683-0168683 to -0169081_125742_S1_M5_c4591001-S-D-suppcm.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0168683 to -0169081_125742_S1_M5_c4591001-S-D-suppcm.xpt,2.75,xpt,,01062022
125742_S1_M5_CRF_c4591001-1013-10131517.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131517.pdf,1.18,pdf,144.0,01062022
125742_S1_M5_CRF_c4591001-1007-10071280.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071280.pdf,1.91,pdf,212.0,01062022
125742_S1_M5_CRF_c4591001-1128-11281009 reissue.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1128-11281009 reissue.pdf,1.88,pdf,364.0,01062022
125742_S1_M5_CRF_c4591001-1015-10151225.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1015-10151225.pdf,1.47,pdf,206.0,01062022
FDA-CBER-2021-5683-0149082 to -0158559_125742_S1_M5_c4591001-S-D-ce.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0149082 to -0158559_125742_S1_M5_c4591001-S-D-ce.xpt,368.08,xpt,,01062022
125742_S1_M5_CRF_c4591001-1012-10121112.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1012-10121112.pdf,1.69,pdf,246.0,01062022
125742_S1_M5_5351_c4591001-fa-interim-patient-batches.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_5351_c4591001-fa-interim-patient-batches.pdf,1.26,pdf,139.0,01062022
125742_S1_M5_5351_c4591001-fa-interim-protocol-deviations-sensitive.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_5351_c4591001-fa-interim-protocol-deviations-sensitive.pdf,1.51,pdf,46.0,01062022
125742_S1_M5_CRF_c4591001-1013-10131699.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131699.pdf,2.34,pdf,412.0,01062022
125742_S1_M5_CRF_c4591001-1011-10111181.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1011-10111181.pdf,1.19,pdf,149.0,01062022
125742_S1_M5_CRF_c4591001-1007-10071443.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071443.pdf,1.31,pdf,157.0,01062022
125742_S1_M5_CRF_c4591001-1009-10091123.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1009-10091123.pdf,1.26,pdf,161.0,01062022
125742_S1_M5_CRF_c4591001-1008-10081337.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1008-10081337.pdf,1.24,pdf,182.0,01062022
125742_S1_M5_CRF_c4591001-1015-10151035.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1015-10151035.pdf,1.24,pdf,154.0,01062022
125742_S1_M5_CRF_c4591001-1009-10091135.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1009-10091135.pdf,1.72,pdf,272.0,01062022
125742_S1_M5_CRF_c4591001-1007-10071441.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071441.pdf,1.25,pdf,169.0,01062022
125742_S1_M5_CRF_c4591001-1013-10131089.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131089.pdf,1.43,pdf,225.0,01062022
125742_S1_M5_CRF_c4591001-1008-10081056.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1008-10081056.pdf,1.21,pdf,173.0,01062022
125742_S1_M5_CRF_c4591001-1007-10071124.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071124.pdf,1.72,pdf,297.0,01062022
125742_S1_M5_CRF_c4591001-1007-10071050.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071050.pdf,3.0,pdf,614.0,01062022
125742_S1_M5_CRF_c4591001-1013-10131658.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131658.pdf,1.07,pdf,122.0,01062022
125742_S1_M5_CRF_c4591001-1015-10151011.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1015-10151011.pdf,1.35,pdf,205.0,01062022
125742_S1_M5_5351_c4591001-interim-mth6-randomization.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_5351_c4591001-interim-mth6-randomization.pdf,1.2,pdf,2.0,01062022
125742_S1_M5_CRF_c4591001-1007-10071101.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071101.pdf,1.48,pdf,201.0,01062022
125742_S1_M5_CRF_c4591001-1013-10131084.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131084.pdf,1.37,pdf,179.0,01062022
125742_S1_M5_CRF_c4591001-1007-10071276.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071276.pdf,1.77,pdf,187.0,01062022
FDA-CBER-2021-5683-0171524 to -0174606_125742_S1_M5_c4591001-S-D-suppds.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0171524 to -0174606_125742_S1_M5_c4591001-S-D-suppds.xpt,16.94,xpt,,01062022
125742_S1_M5_CRF_c4591001-1013-10131656.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131656.pdf,1.22,pdf,175.0,01062022
125742_S1_M5_CRF_c4591001-1015-10151238.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1015-10151238.pdf,2.52,pdf,435.0,01062022
125742_S1_M5_CRF_c4591001-1007-10071315.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071315.pdf,1.42,pdf,172.0,01062022
125742_S1_M5_CRF_c4591001-1007-10071117.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071117.pdf,1.9,pdf,341.0,01062022
125742_S1_M5_CRF_c4591001-1008-10081667.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1008-10081667.pdf,1.27,pdf,186.0,01062022
125742_S1_M5_CRF_c4591001-1013-10131653.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131653.pdf,1.23,pdf,176.0,01062022
125742_S1_M5_5351_c4591001-fa-interim-adverse-events.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_5351_c4591001-fa-interim-adverse-events.pdf,31.71,pdf,2566.0,01062022
FDA-CBER-2021-5683-0180191 to -0182980_125742_S1_M5_c4591001-S-D-suppis.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0180191 to -0182980_125742_S1_M5_c4591001-S-D-suppis.xpt,7.99,xpt,,01062022
125742_S1_M5_CRF_c4591001-1012-10121097.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1012-10121097.pdf,1.81,pdf,286.0,01062022
STN 125742-0-0 Section 2.5 Clinical Overview reissue.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/STN 125742-0-0 Section 2.5 Clinical Overview reissue.pdf,4.72,pdf,334.0,01062022
125742_S1_M5_CRF_c4591001-1013-10131718.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131718.pdf,2.18,pdf,428.0,01062022
125742_S1_M5_CRF_c4591001-1009-10091128.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1009-10091128.pdf,1.62,pdf,228.0,01062022
125742_S1_M5_CRF_c4591001-1007-10071306.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071306.pdf,2.76,pdf,459.0,01062022
125742_S1_M5_CRF_c4591001-1013-10131255.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131255.pdf,1.33,pdf,204.0,01062022
FDA-CBER-2021-5683-0162690 to -0165892_125742_S1_M5_c4591001-S-D-ex.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0162690 to -0165892_125742_S1_M5_c4591001-S-D-ex.xpt,44.73,xpt,,01062022
125742_S1_M5_CRF_c4591001-1011-10111029.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1011-10111029.pdf,1.53,pdf,207.0,01062022
125742_S1_M5_CRF_c4591001-1013-10131554.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131554.pdf,2.32,pdf,463.0,01062022
125742_S1_M5_5351_c4591001-interim-mth6-publications.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_5351_c4591001-interim-mth6-publications.pdf,11.18,pdf,52.0,01062022
FDA-CBER-2021-5683-0182981 to -0187905_125742_S1_M5_c4591001-S-D-suppmh.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0182981 to -0187905_125742_S1_M5_c4591001-S-D-suppmh.xpt,21.61,xpt,,01062022
125742_S1_M5_CRF_c4591001-1008-10081603.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1008-10081603.pdf,1.31,pdf,173.0,01062022
125742_S1_M5_CRF_c4591001-1015-10151071.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1015-10151071.pdf,1.23,pdf,155.0,01062022
125742_S1_M5_CRF_c4591001-1013-10131190.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131190.pdf,2.3,pdf,431.0,01062022
125742_S1_M5_CRF_c4591001-1013-10131386.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131386.pdf,0.98,pdf,117.0,01062022
125742_S1_M5_5314_shi-sop-10011.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_5314_shi-sop-10011.pdf,2.08,pdf,16.0,01062022
125742_S1_M5_CRF_c4591001-1008-10081628.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1008-10081628.pdf,1.19,pdf,167.0,01062022
125742_S1_M5_CRF_c4591001-1013-10131786.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1013-10131786.pdf,3.13,pdf,629.0,01062022
125742_S1_M5_CRF_c4591001-1015-10151101.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1015-10151101.pdf,1.05,pdf,133.0,01062022
125742_S1_M5_CRF_c4591001-1009-10091149.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1009-10091149.pdf,1.47,pdf,205.0,01062022
125742_S1_M5_CRF_c4591001-1007-10071159.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1007-10071159.pdf,1.29,pdf,178.0,01062022
FDA-CBER-2021-5683-0169082 to -0171523_125742_S1_M5_c4591001-S-D-suppdm.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0169082 to -0171523_125742_S1_M5_c4591001-S-D-suppdm.xpt,13.7,xpt,,01062022
FDA-CBER-2021-5683-0187906 to -0196048_125742_S1_M5_c4591001-S-D-suppvs.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0187906 to -0196048_125742_S1_M5_c4591001-S-D-suppvs.xpt,39.15,xpt,,01062022
FDA-CBER-2021-5683-0205318 to -0208520_125742_S1_M5_c4591001-S-Supp-D-ex.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0205318 to -0208520_125742_S1_M5_c4591001-S-Supp-D-ex.xpt,44.73,xpt,,01062022
FDA-CBER-2021-5683-0142307 to -0149081_125742_S1_M5_c4591001-A-Supp-D-adcevd.xpt,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/FDA-CBER-2021-5683-0142307 to -0149081_125742_S1_M5_c4591001-A-Supp-D-adcevd.xpt,425.98,xpt,,01062022
125742_S1_M5_CRF_c4591001-1015-10151089.pdf,/Users/arihantchoudhary/GitHub/Klarity/uploads/Pfizer/Rel_01062022/125742_S1_M5_CRF_c4591001-1015-10151089.pdf,1.24,pdf,145.0,01062022
